Jabarkan Peraturan dari Terapi belatung

In January 2004, the U.S. Food and Drug Administration (FDA) granted permission to produce and market maggots for use in humans or animals as a prescription-only medical device for the following indications: "For debriding non-healing necrotic skin and soft tissue wounds, including pressure ulcers, venous stasis ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds." In February 2004, the British National Health Service (NHS) permitted its doctors to prescribe maggot therapy. In the European Union, Canada and Japan, maggots are classified as medicinal drugs, needing a full market licence. In the U.S., maggots for medicinal use are classified as a device.

Sun, Xinjuan; Jiang, Kechun; Chen, Jingan; Wu, Liang; Lu, Hui; Wang, Aiping; Wang, Jianming (2014). "A systematic review of maggot debridement therapy for chronically infected wounds and ulcers". International Journal of Infectious Diseases 25: 32–7. doi:10.1016/j.ijid.2014.03.1397. PMID 24841930.

Tian, X; Liang, XM; Song, GM; Zhao, Y; Yang, XL (September 2013). "Maggot debridement therapy for the treatment of diabetic foot ulcers: a meta-analysis". Journal of wound care 22 (9): 462–9. PMID 24005780.